Trial Profile
A Randomized, Double-blind, Placebo-controlled Adjuvant Trial in Newly Diagnosed Primary Glioblastoma Subjects to Assess the Efficacy and Safety of LAM561 in Combination With Radiotherapy and Temozolomide Standard of Care Treatment.
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs 2-hydroxyoleic acid (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms CLINGLIO
- Sponsors Laminar Pharmaceuticals
- 10 Apr 2024 Planned primary completion date changed from 28 Feb 2024 to 15 Oct 2024.
- 06 Mar 2024 According to a Laminar Pharmaceuticals media release,the CLINGLIO trial is considered pivotal in that results showing significant clinical benefit could be sufficient for a request for conditional marketing authorization in the EU late this year; and potential full marketing authorization in 2025, for which enabling pre-submission interactions with the EMA have been initiated.
- 06 Mar 2024 Interim results presented in a Laminar Pharmaceuticals Media Release.